RecruitingNCT04630613
NOX4 and Related Biomarkers in ADPKD
NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease
Sponsor
Mayo Clinic
Enrollment
60 participants
Start Date
Jul 21, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
Eligibility
Min Age: 15 YearsMax Age: 40 Years
Inclusion Criteria5
- ADPKD (based on Ravine et al. criteria)
- Class 1 A-E according to imaging classification
- Male and female subjects 15 - 40 years of age
- Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI)
- Ability to provide written, informed consent
Exclusion Criteria6
- Class 2 according to imaging classification
- Concomitant systemic disease affecting the kidney
- Diabetes mellitus
- Predicted urine protein excretion in \>1 g/24 hrs
- Use of antioxidants i.e. vitamins, Nrf2 activators
- Abnormal urinalysis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04630613
Related Trials
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
NCT0493993549 locations
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT0722836415 locations
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT0690255875 locations
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT043447691 location
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
NCT064358582 locations